230 related articles for article (PubMed ID: 24094893)
1. Tumour expresion of tissue factor and tissue factor pathway inhibitor in ovarian cancer- relationship with venous thrombosis risk.
Abu Saadeh F; Norris L; O'Toole S; Mohamed BM; Langhe R; O'Leary J; Gleeson N
Thromb Res; 2013 Nov; 132(5):627-34. PubMed ID: 24094893
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms and plasma levels of tissue factor and tissue factor pathway inhibitor in venous thromboembolism.
Kwon A; Jo SH; Jo YA; Park JY; Kim M; Kang HJ; Kim HS; Cho HC; Lee YK
Blood Coagul Fibrinolysis; 2014 Jul; 25(5):416-21. PubMed ID: 24448154
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of venous thrombosis and tissue factor in epithelial ovarian cancer.
Cohen JG; Prendergast E; Geddings JE; Walts AE; Agadjanian H; Hisada Y; Karlan BY; Mackman N; Walsh CS
Gynecol Oncol; 2017 Jul; 146(1):146-152. PubMed ID: 28501328
[TBL] [Abstract][Full Text] [Related]
4. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis.
Kaikita K; Takeya M; Ogawa H; Suefuji H; Yasue H; Takahashi K
J Pathol; 1999 Jun; 188(2):180-8. PubMed ID: 10398162
[TBL] [Abstract][Full Text] [Related]
5. Shiga toxin downregulates tissue factor pathway inhibitor, modulating an increase in the expression of functional tissue factor on endothelium.
Grabowski EF; Kushak RI; Liu B; Ingelfinger JR
Thromb Res; 2013 Jun; 131(6):521-8. PubMed ID: 23642803
[TBL] [Abstract][Full Text] [Related]
6. Tumor expression, plasma levels and genetic polymorphisms of the coagulation inhibitor TFPI are associated with clinicopathological parameters and survival in breast cancer, in contrast to the coagulation initiator TF.
Tinholt M; Vollan HK; Sahlberg KK; Jernström S; Kaveh F; Lingjærde OC; Kåresen R; Sauer T; Kristensen V; Børresen-Dale AL; Sandset PM; Iversen N
Breast Cancer Res; 2015 Mar; 17(1):44. PubMed ID: 25882602
[TBL] [Abstract][Full Text] [Related]
7. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer.
Uno K; Homma S; Satoh T; Nakanishi K; Abe D; Matsumoto K; Oki A; Tsunoda H; Yamaguchi I; Nagasawa T; Yoshikawa H; Aonuma K
Br J Cancer; 2007 Jan; 96(2):290-5. PubMed ID: 17211468
[TBL] [Abstract][Full Text] [Related]
8. [Association of single nucleotide polymorphisms of tissue factor and tissue factor pathway inhibitor with venous thromboembolism in patients with lung cancer].
Zhang XL; Zhu J; Chen WH; Zhai ZG; Zhang YH
Zhonghua Yi Xue Za Zhi; 2018 Mar; 98(12):901-906. PubMed ID: 29665662
[No Abstract] [Full Text] [Related]
9. Expression of tissue factor pathway inhibitor (TFPI) in human breast and colon cancer tissue.
Sierko E; Wojtukiewicz MZ; Zimnoch L; Kisiel W
Thromb Haemost; 2010 Jan; 103(1):198-204. PubMed ID: 20062932
[TBL] [Abstract][Full Text] [Related]
10. Expression of tissue factor and tissue factor pathway inhibitor in microparticles and subcellular fractions of normal and malignant prostate cell lines.
Lwaleed BA; Lam L; Lasebai M; Cooper AJ
Blood Coagul Fibrinolysis; 2013 Apr; 24(3):339-43. PubMed ID: 23524311
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms of the tissue factor pathway inhibitor gene are associated with venous thromboembolism in the antiphospholipid syndrome and carriers of factor V Leiden.
Lincz LF; Adams MJ; Scorgie FE; Thom J; Baker RI; Seldon M
Blood Coagul Fibrinolysis; 2007 Sep; 18(6):559-64. PubMed ID: 17762532
[TBL] [Abstract][Full Text] [Related]
12. PO-24 - Determinants of thrombin generation in gynaecological malignancies.
Norris LA; Martin FA; O'Toole SA; Saadeh FA; Gleeson N
Thromb Res; 2016 Apr; 140 Suppl 1():S185. PubMed ID: 27161714
[TBL] [Abstract][Full Text] [Related]
13. Elevated levels of leukocyte tissue factor mRNA in patients with venous thromboembolism.
Kamikura Y; Wada H; Nobori T; Kobayashi T; Sase T; Nishikawa M; Ishikura K; Yamada N; Abe Y; Nishioka J; Nakano T; Shiku H
Thromb Res; 2005; 116(4):307-12. PubMed ID: 16038715
[TBL] [Abstract][Full Text] [Related]
14. Microparticle-associated tissue factor activity and venous thrombosis in multiple myeloma.
Auwerda JJ; Yuana Y; Osanto S; de Maat MP; Sonneveld P; Bertina RM; Leebeek FW
Thromb Haemost; 2011 Jan; 105(1):14-20. PubMed ID: 21057704
[TBL] [Abstract][Full Text] [Related]
15. [Value of plasma tissue factor, tissue factor pathway inhibitor and factor VII assessments in patients with acute myocardial and cerebral infarction].
Xiong SL; Wang Q; Zheng L; Li JL; Wen ZB; He SL
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Dec; 27(12):1821-3. PubMed ID: 18158992
[TBL] [Abstract][Full Text] [Related]
16. Microvesicle-associated tissue factor procoagulant activity for the preoperative diagnosis of ovarian cancer.
Claussen C; Rausch AV; Lezius S; Amirkhosravi A; Davila M; Francis JL; Hisada YM; Mackman N; Bokemeyer C; Schmalfeldt B; Mahner S; Langer F
Thromb Res; 2016 May; 141():39-48. PubMed ID: 26967531
[TBL] [Abstract][Full Text] [Related]
17. Intratumoral tissue factor expression and risk of venous thromboembolism in brain tumor patients.
Thaler J; Preusser M; Ay C; Kaider A; Marosi C; Zielinski C; Pabinger I; Hainfellner JA
Thromb Res; 2013 Feb; 131(2):162-5. PubMed ID: 23084660
[TBL] [Abstract][Full Text] [Related]
18. [Study of the effect of TF/FVIIa complex on the expression of u-PAR mRNA in human ovarian cancer].
Fang J; Wei WN; Xia LH; Song SJ
Zhonghua Xue Ye Xue Za Zhi; 2004 Mar; 25(3):143-6. PubMed ID: 15182581
[TBL] [Abstract][Full Text] [Related]
19. Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma.
Han LY; Landen CN; Kamat AA; Lopez A; Bender DP; Mueller P; Schmandt R; Gershenson DM; Sood AK
J Clin Oncol; 2006 Feb; 24(5):755-61. PubMed ID: 16380413
[TBL] [Abstract][Full Text] [Related]
20. Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels.
Crawley J; Lupu F; Westmuckett AD; Severs NJ; Kakkar VV; Lupu C
Arterioscler Thromb Vasc Biol; 2000 May; 20(5):1362-73. PubMed ID: 10807755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
